Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MesoblastSTU:LWB -2.01%56 Cyclically Adjusted PS Ratio is 45.20 as of Sep. 16, 2026, which is 188% above its 10-year median of 15.72. GuruFocus rates STU:LWB with a GF Score™ of 56/100. The stock has 2 warning signs investors should review. Among 532 Biotechnology companies, Mesoblast ranks worse than 187969.74% on this metric.
The historical rank and industry rank for Mesoblast's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past 13 years, Mesoblast's highest Cyclically Adjusted PS Ratio was 27.65. The lowest was 5.69. And the median was 15.72.
STU:LWB's Cyclically Adjusted PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 5.78 * Ranked among companies with meaningful Cyclically Adjusted PS Ratio only.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Mesoblast's adjusted revenue per share data of for the fiscal year that ended in Jun26 was €0.080. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €0.03 for the trailing ten years ended in Jun26.
Shiller PE for Stocks: The True Measure of Stock Valuation
Mesoblast (STU:LWB) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Mesoblast Cyclically Adjusted PS Ratio Related Terms
Mesoblast Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Mesoblast's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:LWB vs VRTX, REGN, MRNA: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Mesoblast's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mesoblast Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mesoblast's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Mesoblast's Cyclically Adjusted PS Ratio falls into.
Mesoblast Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Mesoblast's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 45.20 mean?
Mesoblast (STU:LWB) has a Cyclically Adjusted PS Ratio of 45.20 as of Sep. 16, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Mesoblast and its competitors. This is 188% above median its historical median of 15.72. Over the past decade, Mesoblast's Cyclically Adjusted PS Ratio has ranged from 5.69 to 27.65. According to the industry distribution chart, Mesoblast ranks #999999 out of 532 companies in the Biotechnology industry.
Is Mesoblast's Cyclically Adjusted PS Ratio too high?
Mesoblast's current Cyclically Adjusted PS Ratio of 45.20 is 188% above median its 10-year median of 15.72. Over the past 10 years, this metric has ranged from a low of 5.69 to a high of 27.65. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.78. Mesoblast's value of 45.20 is 682% above this industry median. Based on the distribution chart, Mesoblast ranks #999999 out of 532 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Mesoblast has a GF Score™ of 56/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Mesoblast ranks #999999 out of 532 companies for Cyclically Adjusted PS Ratio. This places Mesoblast in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.78. Mesoblast's value of 45.20 is 682% above this benchmark. Historically, Mesoblast's own Cyclically Adjusted PS Ratio has ranged from 5.69 to 27.65 over the past decade. While the company's 10-year median is 15.72 vs. the industry median of 5.78, Mesoblast has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.78, based on 532 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mesoblast's current Cyclically Adjusted PS Ratio of 45.20 is 682% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Mesoblast and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mesoblast's current Cyclically Adjusted PS Ratio is 45.20, which is 188% above median its own 10-year median of 15.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (STU:LWB) has a current Cyclically Adjusted PS Ratio of 45.20. The current Cyclically Adjusted PS Ratio is 45.20, which is 188% above median its 10-year median of 15.72 and 682% above the Biotechnology industry median of 5.78. Mesoblast's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Mesoblast (STU:LWB), the current Cyclically Adjusted PS Ratio is 45.20 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
56GF Score
Get the complete analysis for STU:LWB
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:LWB has been successfully added to your 
